{
    "clinical_study": {
        "@rank": "90532", 
        "arm_group": [
            {
                "arm_group_label": "CD07805/47 gel 0.5%/CD07805/47 Vehicle", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who will receive CD07805/47 gel 0.5% and CD07805/47 gel vehicle during Period 1 (baseline to Day 15) per subject's randomization scheme will switch treatment arms in Period 2. Subjects who do not receive CD07805/47 gel 0.5% and CD07805/47 gel vehicle during Period 1 will receive CD07805/47 gel 0.5% and CD07805/47 gel vehicle in Period 2 (baseline to Day 15)."
            }, 
            {
                "arm_group_label": "azelaic acid gel 15%", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects who will receive azelaic acid gel 15% during Period 1 (baseline to Day 15) per subject's randomization scheme will switch treatment arms in Period 2. Subjects who do not receive azelaic acid gel 15% during Period 1 will receive azelaic acid gel 15% in Period 2 (baseline to Day 15)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel\n      0.5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily\n      in subjects with moderate to severe facial erythema of rosacea."
        }, 
        "brief_title": "Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Erythema", 
            "Rosacea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rosacea", 
                "Erythema"
            ]
        }, 
        "detailed_description": {
            "textblock": "Adult subjects with moderate to severe facial erythema of rosacea who meet\n      inclusion/exclusion criteria will be randomized at Baseline/Visit 1 in a 1:1 ratio to\n      receive either CD07805/47 gel 0.5% once daily or azelaic acid gel 15% twice daily for 15\n      days. Following an appropriate washout period, subjects will then switch treatments and use\n      the second investigational product as instructed for 15 days (according to the subject's\n      randomization scheme). Subjects will re-qualify based upon inclusion/exclusion prior to\n      Period 2 treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is male or female aged 18 years or older.\n\n          2. Subject has a clinical diagnosis of facial rosacea.\n\n          3. Subject has a clinician's assessment score of moderate to severe erythema prior to\n             enrollment.\n\n          4. Subject has a self assessment score of moderate to severe redness prior to\n             enrollment.\n\n          5. Subjects with none to mild facial inflammatory lesions of rosacea prior to\n             enrollment.\n\n        Exclusion Criteria:\n\n          1. Female subjects who are pregnant, nursing or planning a pregnancy during the study.\n\n          2. Subjects with a condition or who are in a situation, which in the Investigator's\n             opinion may put a subject at risk, may confound study results, or may interfere with\n             a subject's participation in the study.\n\n          3. Subjects with conditions causing facial erythema which would confound the assessment\n             of treatment.\n\n          4. Subjects who are taking or have recently taken medications known to have interactions\n             with \u03b12-adrenergic agonists.\n\n          5. Subjects with known allergies or sensitivities to one of the components of the\n             investigational products."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659853", 
            "org_study_id": "US10219"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD07805/47 gel 0.5%/CD07805/47 Vehicle", 
                "description": "To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.\nDuring each treatment period (baseline to Day 15):\nCD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily", 
                "intervention_name": "CD07805/47 gel 0.5%/CD07805/47 Vehicle", 
                "intervention_type": "Drug", 
                "other_name": [
                    "brimonidine tartrate gel 0.5%", 
                    "brimonidine tartrate gel vehicle"
                ]
            }, 
            {
                "arm_group_label": "azelaic acid gel 15%", 
                "description": "During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily", 
                "intervention_name": "azelaic acid gel 15%", 
                "intervention_type": "Drug", 
                "other_name": "Finacea\u00ae gel 15%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azelaic acid", 
                "Brimonidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47714"
                    }, 
                    "name": "Hudson Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Dermatology Specialists Research, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "DermResearch, Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lynchburg", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24501"
                    }, 
                    "name": "The Education & Research Foundation, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea", 
        "overall_official": {
            "affiliation": "Galderma Laboratories, L.P.", 
            "last_name": "Ronald W. Gottschalk, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Composite Success, defined as an improvement on both the clinician's and subject's erythema assessments at the end of each treatment period", 
            "measure": "Composite Success", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Day 15 (15 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659853"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Onset of action, defined as an improvement on both the clinician's and subject's erythema assessments at 30 minutes post baseline application", 
            "measure": "Onset of Action", 
            "safety_issue": "No", 
            "time_frame": "30 minutes post baseline treatment application"
        }, 
        "source": "Galderma Laboratories, L.P.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma Laboratories, L.P.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}